Deal-happy Valeant eyes more buyouts, 'merger of equals'

Months after spending $8.7 billion on Bausch + Lomb, Canada's Valeant Pharmaceuticals ($VRX) is hardly done dealmaking, CEO Michael Pearson said. The chief told analysts Valeant is on the lookout for cash deals to expand its pipeline and is keeping its ears open to a "merger of equals." Article

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.